朝日啤酒获有条件批准收购百威英博澳洲业务
朝日啤酒(Asahi)获澳洲竞争监管机构有条件批准,以110亿美元收购全球最大啤酒生产商百威英博(AB inBev)的澳洲业务。
澳洲竞争与消费者委员会(ACCC)表示,在朝日啤酒承诺出售百威英博的Stella Artois及Beck的啤酒品牌,以及Strongbow、Bonamy及Little Green苹果酒品牌後,该交易已获得批准。不过根据协议,朝日啤酒必须确保在未来3年内,上述5个啤酒品牌可以如朝日啤酒品牌一样,在相同的酒吧及俱乐部等出售。
朝日啤酒发言人表示,目前正在等待澳洲外国投资审查委员会(FIRB)的批准,交易仍有望在第二季度完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.